S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
Log in
NASDAQ:ICAD

iCAD Stock Forecast, Price & News

$13.30
+0.26 (+1.99 %)
(As of 01/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.04
Now: $13.30
$13.48
50-Day Range
$9.34
MA: $12.68
$14.56
52-Week Range
$5.91
Now: $13.30
$15.31
Volume99,362 shs
Average Volume133,544 shs
Market Capitalization$305.81 million
P/E RatioN/A
Dividend YieldN/A
Beta1.3
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which offers automated, consistent, and standardized reporting tool used for mammogram. It also provides ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound Panorama, a prototype software product for determining risk factors in interval cancers; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. It serves healthcare centers through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. The company also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire.

MarketRank

Overall MarketRank

1.29 out of 5 stars

Analyst Opinion: 2.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
Current SymbolNASDAQ:ICAD
CUSIPN/A
Phone603-882-5200
Employees135

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.34 million
Book Value$0.26 per share

Profitability

Net Income$-13,550,000.00

Miscellaneous

Market Cap$305.81 million
Next Earnings Date2/25/2021 (Estimated)
OptionableOptionable
$13.30
+0.26 (+1.99 %)
(As of 01/19/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ICAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ICAD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











iCAD (NASDAQ:ICAD) Frequently Asked Questions

How has iCAD's stock price been impacted by Coronavirus?

iCAD's stock was trading at $11.12 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ICAD shares have increased by 19.6% and is now trading at $13.30.
View which stocks have been most impacted by COVID-19
.

Is iCAD a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for iCAD in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" iCAD stock.
View analyst ratings for iCAD
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than iCAD?

Wall Street analysts have given iCAD a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but iCAD wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is iCAD's next earnings date?

iCAD is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for iCAD
.

How were iCAD's earnings last quarter?

iCAD, Inc. (NASDAQ:ICAD) posted its quarterly earnings data on Thursday, November, 5th. The technology company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.04. The technology company earned $7.13 million during the quarter. iCAD had a negative net margin of 67.61% and a negative return on equity of 55.84%.
View iCAD's earnings history
.

What price target have analysts set for ICAD?

4 brokers have issued 12-month price objectives for iCAD's shares. Their forecasts range from $15.00 to $18.00. On average, they anticipate iCAD's stock price to reach $16.25 in the next twelve months. This suggests a possible upside of 22.2% from the stock's current price.
View analysts' price targets for iCAD
or view Wall Street analyst' top-rated stocks.

Are investors shorting iCAD?

iCAD saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 977,800 shares, an increase of 22.5% from the December 15th total of 798,000 shares. Based on an average daily volume of 189,100 shares, the days-to-cover ratio is presently 5.2 days.
View iCAD's Short Interest
.

Who are some of iCAD's key competitors?

What other stocks do shareholders of iCAD own?

Who are iCAD's key executives?

iCAD's management team includes the following people:
  • Mr. Michael S. Klein, Exec. Chairman & CEO (Age 66, Pay $495.37k)
  • Ms. Stacey M. Stevens, Pres (Age 52, Pay $514.82k)
  • Mr. Jonathan Go, Chief Technology Officer (Age 57, Pay $460.85k)
  • Mr. Richard Scott Areglado, Chief Financial Officer (Age 56)
  • Ms. Annette L. Heroux, VP of Admin. (Age 63)
  • Mr. Jeffrey Sirek, Sr. VP & Gen. Mang. of Xoft

What is iCAD's stock symbol?

iCAD trades on the NASDAQ under the ticker symbol "ICAD."

Who are iCAD's major shareholders?

iCAD's stock is owned by many different institutional and retail investors. Top institutional shareholders include Mesirow Financial Investment Management Inc. (0.15%) and Traynor Capital Management Inc. (0.11%). Company insiders that own iCAD stock include Andy Sassine, R Scott Areglado and Stacey M Stevens.
View institutional ownership trends for iCAD
.

Which major investors are buying iCAD stock?

ICAD stock was purchased by a variety of institutional investors in the last quarter, including Traynor Capital Management Inc., and Mesirow Financial Investment Management Inc..
View insider buying and selling activity for iCAD
or or view top insider-buying stocks.

How do I buy shares of iCAD?

Shares of ICAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is iCAD's stock price today?

One share of ICAD stock can currently be purchased for approximately $13.30.

How big of a company is iCAD?

iCAD has a market capitalization of $305.81 million and generates $31.34 million in revenue each year. The technology company earns $-13,550,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. iCAD employs 135 workers across the globe.

What is iCAD's official website?

The official website for iCAD is www.icadmed.com.

How can I contact iCAD?

iCAD's mailing address is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. The technology company can be reached via phone at 603-882-5200 or via email at [email protected]

This page was last updated on 1/19/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.